

28 June 2021

Price	SEK 2.95
Fair value	SEK 7
Market capitalisation	SEK 1,325 million
Enterprise value	SEK 1,215 million
12m high/low	SEK 5.75 / SEK 2.82
Avg. daily volume	3.8m
Bloomberg / Reuters	OASM.SS / OASM.ST
Exchange	Stockholm
Adviser	Yes
Next results (Q2)	19 August 2021

## Top 5 Shareholders

Per Arwidsson	24.8%
Avanza Pension	6.6%
Mastan AB (Håkan Lagerberg)	2.1%
Nordnet Pension Insurance	1.7%
Swedbank Insurance	1.5%

## Analysts

Dr Joseph Hedden (Biotechnology & Pharma)  
joseph@rxsecurities.com +44 (0) 207 993 8244


Dr Samir Devani  
samir@rxsecurities.com +44 (0) 207 993 8210

Michael King (Medical Technology)  
michael@rxsecurities.com +44 (0) 207 993 8249

## Corporate Broking

Julian Burn-Callander  
julian@rxsecurities.com +44 (0) 207 993 8210

## Share price performance (1 year)



## Oasmia Pharmaceutical AB

### Inceptua to now commercialise Apealea® in the Nordics

Oasmia Pharmaceutical has announced that it has transferred the rights to commercialise its key value-driver Apealea® (an enhanced formulation of paclitaxel for ovarian cancer) in the Nordic countries to Inceptua Group. Under the terms of the deal, Oasmia is eligible to receive double-digit percentage royalties on sales of Apealea® in the Nordics. We believe this is a sensible deal as Inceptua had already obtained rights to commercialise the drug in other European countries under a deal with Oasmia's partner Elevar Therapeutics in December 2020 (see below) – we expect that the streamlining of Oasmia's operations will enable some cost savings that can be funnelled towards progressing its current R&D pipeline assets docetaxel micellar (Phase Ib trial in prostate cancer just started dosing) and cantrixil (we anticipate entering Phase II next year), as well as advancing its “string of pearls” strategy to further grow the oncology portfolio. We continue to project Inceptua conducting the first launches of Apealea® in European countries in H2 2021, while we believe Elevar could initiate new trials also in H2 to support a future NDA (we forecast US launch in 2025). We have revised our forecasts to reflect the structure of this deal and consequent modest cost savings. With sales in the Nordics only a fraction of our forecasts for peak sales of Apealea® for \$275 million in the US and Europe, the new economics have no material impact on our valuation of Oasmia – we maintain our BUY rating and fair value of SEK 7/share.

- **Elevar sublicensed Apealea® in Europe with Inceptua in December 2020** – the economics due to Oasmia under its deal with Elevar are unchanged – development, regulatory and sales milestones up to \$678 million, and double-digit percentage royalties on sales. Inceptua's Pharma division has infrastructure across Europe and the Middle East, marketing orphan and specialty care products including Farydak® (panobinostat, developed by Novartis), a drug to treat relapsed/refractory multiple myeloma.
- **Phase Ib trial of docetaxel micellar in mCRPC underway** – this open-label, 3+3 design dose-escalation trial is to recruit up to 18 chemotherapy-naïve mCRPC patients. Patients are to be treated with up to 10, 21-day cycles of one of three dose levels of docetaxel. The primary endpoint is to determine the maximum tolerated dose, and secondary efficacy endpoints include progression-free survival and prostate-specific antigen progression. The study has a primary endpoint completion date (as listed on ClinicalTrials.gov) of June 2023.

## Key financial data (MSEK) – IFRS

Y/E 31 Dec	2020A*	2021E	2022E	2023E	2024E
Revenue	0.5	11.3	29.0	29.9	63.5
EBITDA	(102.6)	(124.9)	(131.0)	(125.1)	(101.4)
Net Income	(140.3)	(158.0)	(164.6)	(159.5)	(136.6)
EPS (SEK)	(0.3)	(0.4)	(0.4)	(0.4)	(0.3)
Net Cash	207.4	51.8	(74.2)	(194.3)	(290.8)

Source: Rx Securities estimates ; \*1 May 2020 to 31 December 2020, in January 2021 Oasmia's financial year-end changed from 30 April to 31 December

Consensus	2021E	2022E	2023E	2024E
Revenue	14.6	41.2	54.2	82.2
EBITDA	(125.0)	(109.9)	(105.3)	(90.1)

Source: Bloomberg

Rx Securities (www.rxsecurities.com) is authorised and regulated by the Financial Conduct Authority

This document is a marketing communication and is not independent research prepared in accordance with legal requirements designed to promote the independence of investment research. Please see our disclaimer and MiFID II statement on page 2 for further information.

## Important Disclosures

I, Joseph Hedden, hereby certify that the views about the companies and their securities discussed in this report are accurately expressed and I have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report.

R<sub>x</sub> Securities publishes investment recommendations, which reflect the analyst's assessment of a stock's potential absolute total return. Our research offers 3 recommendations: BUY stocks are expected to have an absolute total return of at least 20%. HOLD stocks are expected to have an absolute total return of between 0-20%. SELL stocks are those which expect to produce a negative return. The time horizon for which the recommendation is deemed valid is 12 months unless otherwise specified in the particular research.

Information relating to any company or security is for information purposes only and should not be interpreted as a solicitation to buy or sell any security or to make any investment. The Information in this communication has been compiled from sources believed to be reliable but it has not been independently verified. No representation is made as to its accuracy or completeness, no reliance should be placed on it and no liability is accepted for any loss arising from reliance on it. All expressions of opinion are subject to change without notice. Opinion may be personal to the author and may not reflect the opinions of R<sub>x</sub> Securities Ltd ('RXS').

RXS's Research publications are not for Retail Clients as defined by the Financial Conduct Authority ('FCA'). The information contained in research publications are obtained from various sources believed to be reliable, but have not been independently verified by RXS. RXS does not warrant the completeness or accuracy of such information and does not accept any liability with respect to the accuracy or completeness of such information, except to the extent required by applicable law. Research publications are for information purposes only and shall not be construed as an offer or solicitation for the subscription or purchase or sale of any securities, or as an invitation, inducement or intermediation for the sale, subscription or purchase of any securities, or for engaging in any other transaction. Research publications are not for private individuals. Any opinions, projections, forecasts or estimates in research reports are those of the author only, who has acted with a high degree of expertise. They reflect only the current views of the author at the date of the report and are subject to change without notice. RXS has no obligation to update, modify or amend any publication or to otherwise notify a reader or recipient of a publication in the event that any matter, opinion, projection, forecast or estimate contained herein, changes or subsequently becomes inaccurate, or if research on the subject company is withdrawn. The analysis, opinions, projections, forecasts and estimates expressed in research reports were in no way affected or influenced by the issuer. The authors of research publications benefit financially from the overall success of RXS. The investments referred to in research publications may not be suitable for all recipients. Recipients are urged to base their investment decisions upon their own appropriate investigations that they deem necessary. Any loss or other consequence arising from the use of the material contained in a research publication shall be the sole and exclusive responsibility of the investor and RXS accepts no liability for any such loss or consequence. In the event of any doubt about any investment, recipients should contact their own investment, legal and/or tax advisers to seek advice regarding the appropriateness of investing. Some of the investments mentioned in research publications may not be readily liquid investments. Consequently it may be difficult to sell or realize such investments. The past is not necessarily a guide to future performance of an investment. The value of investments and the income derived from them may fall as well as rise and investors may not get back the amount invested. Some investments discussed in research publications may have a high level of volatility. High volatility investments may experience sudden and large falls in their value which may cause losses. International investing includes risks related to political and economic uncertainties of foreign countries, as well as currency risk. To the extent permitted by applicable law, no liability whatsoever is accepted for any direct or consequential loss, damages, costs or prejudices whatsoever arising from the use of research publications or their contents.

RXS has written procedures designed to identify and manage potential conflicts of interest that arise in connection with its research business. Chinese Wall procedures are in place between the research analysts and staff involved in corporate finance to ensure that price sensitive information is handled according to applicable laws and regulations.

R<sub>x</sub> Securities has received compensation from this company for the provision of advisory services within the previous twelve months.

**United Kingdom:** Research publications are for persons who are Eligible Counterparties or Professional Clients only and is exempt from the general restriction in section 21 of the Financial Services and Markets Act 2000 on the communication of invitations or inducements to engage in investment activity on the grounds that it is being distributed in the United Kingdom only to persons of a kind described in Articles 19(5) (Investment professionals) and 49(2) (High net worth companies, unincorporated associations etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended). It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons. Any investments to which the research publications relate are available only to such persons, and other classes of person should not rely on the research publications. For the purpose of UK regulation, RXS produces both independent and non-independent research which is a marketing communication under the FCA Conduct of Business rules and has not been prepared in accordance with the legal requirements to promote independence of investment research nor is it subject to the prohibition on dealing ahead of the dissemination of investment research. However, the firm does have procedures in place to manage conflicts which may arise in the production of research, please refer to RXS research policy, which, inter alia, prevents dealing ahead. The research and conflicts of interest policies can be obtained from the Compliance Officer at RXS. Authorised and regulated by the Financial Conduct Authority No. 741031. Registered in England & Wales No. 08995119. The registered address is 23 Austin Friars, London. EC2N 2QP. Tel: +44 (0)20 7993 8210.

**EU Investors:** This communication is issued by R<sub>x</sub> Securities ('RXS'). RXS is authorised and regulated in the United Kingdom by the Financial Conduct Authority in connection with its distribution and for the conduct of designated investment business in the European Economic Area. MiFID II Compliance Statement: RXS Research is paid for by our corporate clients and, as such, falls within the scope of 'minor non-monetary benefits'. Furthermore, RXS is not inducing the reader of our research to trade through us, since RXS does not undertake trade execution.

**US Persons:** RXS is not a registered broker-dealer in the United States of America and therefore is not subject to US rules regarding the preparation of research reports and the independence of research analysts. This research report is provided for distribution in the United States solely to "major US institutional investors" as defined by Rule 15a-6 under the Securities Exchange Act of 1934.

**Other countries:** Laws and regulations of other countries may also restrict the distribution of this report. Persons in possession of Research publications should inform themselves about possible legal restrictions and observe them accordingly.